LGND — Ligand Pharmaceuticals Incorporated Share News
0.000.00%
Last trade - 00:00- $5.95bn
- $5.72bn
- $215.02m
Ligand Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Ligand Pharmaceuticals Q4 EPS USD 1.03
Ligand Pharmaceuticals Inc expected to post earnings of 66 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
U.S. STOCKS ON THE MOVE-Moderna, Coinbase, Ambrx Biopharma
Ligand Pharma up after at-home viral skin infection treatment gets US approval
Brief: U.S. Food And Drug Administration Approves ZELSUVMI™ As A First-In-Class Medication For The Treatment Of Molluscum Contagiosum
Ligand Pharma up after US FDA nod for its topical skin drug
Ligand Pharma's at-home skin treatment gets FDA approval (updated)
Ligand Pharma's topical skin drug gets US FDA approval
Brief: Palvella Therapeutics And Ligand Pharmaceuticals Expand Strategic Partnership To Accelerate Phase 3 Development Of Qtorin™ Rapamycin For Microcystic Lymphatic Malformations
Brief: Ligand Pharmaceuticals Q3 EPS USD -0.74
Brief: Ligand Acquires Royalty On Sanofi’S Tzield® For $20 Million
Brief: Ovid Therapeutics, Ligand Pharmaceuticals Enter Into $30 Mln Agreement For 13% Interest In Soticlestat Royalties and Milestones
Brief: Ligand Acquires Assets Of Novan, Inc. For $12.2 Million
Brief: Ligand Spins Out And Merges Pelican Subsidiary With Primordial Genetics To Form Primrose Bio
Ligand Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Ligand Pharmaceuticals Q2 EPS USD 0.13